Navigation Links
Neurim Pharmaceuticals Grants Exeltis Marketing Rights for Paediatric Prolonged-Release Melatonin ("PedPRM") in Spain
Date:3/29/2017

TEL AVIV, Israel, March 29, 2017 /PRNewswire/ --

Neurim Pharmaceuticals ("Neurim") and Exeltis announced today a license agreement in which Exeltis will obtain exclusive marketing rights for Neurim's new Rx PedPRM in Spain.

Neurim's paediatric prolonged-release Melatonin is an age-appropriate drug targeted to treat sleep disorders in children with Autism Spectrum Disorders (ASD) and neurogenetic diseases. It is expected to be the first sleep medication approved for children.

The collaboration with Exeltis will help increase the accessibility of the new drug to children and their families. "We are delighted to be working with Exeltis and bring this much needed treatment to Spain. Neurim continues to focus on executing its goal of making PedPRM commercially available in all markets," said Sharon Elkobi, VP Business Development of Neurim Pharmaceuticals.

Alberto Fábregas, Managing Director of Exeltis Healthcare in Spain added, "We will be working hard with Neurim to bring this much needed treatment to these children suffering from insomnia in Spain. We are proud of our cooperation with Neurim that started as licensees of Circadin in Spain. This new agreement will reinforce our specialization in insomnia and our presence in Neurology."

About PedPRM 

PedPRM is a response to an unmet clinical need in the field of paediatric insomnia, specifically developed to address main concerns in children with ASD and neurogenetic diseases. PedPRM is an age-appropriate formulation designed for populations with swallowing difficulties.

PedPRM completed a Phase III study, under EU-PIP and US-FDA IND, showing positive top-line results. The drug met the primary efficacy endpoint demonstrating statistically significant improvement in Total Sleep Time (TST) compared to placebo. Secondary efficacy endpoints demonstrating improvements in sleep initiation and maintenance were met as well.

About Neurim Pharmaceuticals 

Neurim Pharmaceuticals Ltd. (http://www.neurim.com) is a neuroscience drug discovery and development company. Its first approved drug Circadin® is commercially available in Europe, Asia-Pacific, Latin America, Africa and the Middle East. The company has a strong and innovative product pipeline intended for insomnia, Alzheimer's disease, dementia, glaucoma and pain.

About Exeltis 

Exeltis, the branded pharmaceutical division of Chemo Group, combines the knowledge and experience gained by the group in almost forty years with the values of entrepreneurial spirit, diversity and excellence. With a sound positioning in the Women's Health, CNS, Respiratory, Dermatology and Ophthalmology, it has a portfolio of almost 300 medicines and presence in more than 40 countries.

Contact
Sharon Elkobi
VP Business Development
sharone@neurim.com


'/>"/>
SOURCE Neurim Pharmaceuticals
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Neurim Pharmaceuticals Grants Aspen Australia Marketing Rights for Paediatric Prolonged-Release Melatonin ("PedPRM") in Australia and New Zealand
2. Neurim Pharmaceuticals Paediatric Prolonged-Release Melatonin (PedPRM) to be Marketed by Biocodex in France
3. Cumberland Pharmaceuticals To Present At The UBS Global Healthcare Conference In New York
4. Valeant Pharmaceuticals Announces Resignation of Dr. Laurence Paul from Valeants Board of Directors
5. DelMar Pharmaceuticals, Inc. Provides Corporate Update for the Quarter Ended March 31, 2013
6. Access Pharmaceuticals Reports First Quarter Results
7. The Zacks Analyst Blog Highlights: Genomic Health, Sanofi, Regeneron Pharmaceuticals, Amgen and Isis Pharmaceuticals
8. Actinium Pharmaceuticals Clinical Results to be Presented at 8th International Symposium on Targeted Alpha Therapy Conference
9. AcelRx Pharmaceuticals to Present at the UBS Global Healthcare Conference
10. Aveo Pharmaceuticals, Inc. Sued by Investor
11. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In AVEO Pharmaceuticals, Inc. To Contact The Firm
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2017)... Michael Penna , President and CEO ... for growth in his response to the July 13, ... seeking a buyer for eMDs. Penna,s company, Complete HealthCare ... Value Added Reseller and national leader in the independent ... "As the healthcare market continues to dictate consolidation, healthcare ...
(Date:9/1/2017)... WHIPPANY, N.J. , Sept. 1, 2017  Bayer will ... at the European Society for Medical Oncology (ESMO) 2017 Congress, ... studies presented will include new preclinical and clinical data on ... from two earlier pipeline projects. ... of the best minds in cancer research at ESMO," said ...
(Date:8/29/2017)... LLC, the leading provider of continuous monitoring devices for the early ... Innovative Technology contract from Vizient, Inc., the largest member-driven health care ... ... of peripheral IV infiltration and extravasation events ... The Innovative Technology contract was awarded to ivWatch based on recommendations ...
Breaking Medicine Technology:
(Date:9/26/2017)... ... ... The 2017 American Academy of Cosmetic Surgery World Congress on Liposuction meeting earlier ... about cosmetic procedures to remove and replace fat, but also how stem cells from ... magical, especially when it comes to the cosmetic patient,” says cosmetic surgeon Dr. Richard ...
(Date:9/26/2017)... ... ... to Live in the Millennium”: a gripping take on how the author used personal ... of everyday life and do not affect daily choices. It shows how to act ... and actions that are chosen. “How to Live in the Millennium” is the creation ...
(Date:9/26/2017)... ... September 26, 2017 , ... “Sound of My Song”: an intriguing ... of published author, Karmen Worden, a retired teacher with a passion for music and ... an intriguing and inspiring story on loss, living with depression, and finding love through ...
(Date:9/26/2017)... ... ... life story of the author and the exciting times this adventurer has lived through. “The ... guide and the subject of the book. , “Quickly slapping a large smile on ... it off as a part of the adventure tour, an “added bonus” story they would ...
(Date:9/26/2017)... ... ... Time out for Daddy is a moving story of a family's unconditional ... mistakes. “Time Out for Daddy” is the creation of published author Debra Titus, who ... for children inspired her to write this book. , Published by Christian Faith Publishing, ...
Breaking Medicine News(10 mins):